Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804395 · ClinicalTrials.gov registry record
CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
A clinical trial of Cancer Risk, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT06804395: Recruiting study of Cancer Risk, sponsored by Hackensack Meridian Health.
NCT06804395 is a study of Cancer Risk that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 10,000 participants, below the 12,600-participant average among 7 other Cancer Risk trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06804395, a study of Cancer Risk, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.
Primary Outcome
Compare the number of detected PGVs as measured by a universal multi-gene panel, proactively, in a diverse community-based population of individuals. PGV rate will be compared to NCCN genetic testing criteria at baseline, and to longitudinal cancer outcomes.
Conditions Studied
Study Locations (1)
New Jersey
- Hennessy Institute for Cancer Prevention and Applied Molecular Medicine - Totowa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2034-10-01 |
What NCT06804395 shows while recruiting
NCT06804395 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, below the 12,600-participant average among 7 other Cancer Risk trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Cancer Risk appearing as the primary indexed condition, and to 0 interventions.
NCT06804395 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06804395 about?
NCT06804395 is a clinical study titled "CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management". Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science ...
What is the current status of trial NCT06804395?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2024-10-01. Estimated completion is 2034-10-01.
What conditions does trial NCT06804395 study?
This clinical trial studies the following conditions: Cancer Risk.
Who is sponsoring clinical trial NCT06804395?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804395 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Risk
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mirai-MRI: Validation of AI Models for Breast Cancer Risk
RECRUITING · NA
-
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
RECRUITING
-
Norris ORIEN Total Cancer Care
RECRUITING
-
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RECRUITING
-
Morehouse Total Cancer Care Protocol
RECRUITING
-
A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI